Episode 48: ASCO 2023 - Prostate, Bladder and Renal Cancer

Written By Inquisitive Oncology

ASCO 23 explored novel anti-cancer agents in the genitourinary space. The future of oncology is etching closer daily. In this episode, Michael and Josh dissect ertafitinib, an FGFR inhibitor used in bladder cancer, talazoparib in prostate cancer and immunotherapy and TKI combinations in renal cell cancer. All these studies reflect the desire to target cancers further with some astonishing results.

Inquisitive Oncology
Previous

Episode 49. ASCO 2023 - Metastatic Breast Cancer
Next

Episode 47: ASCO 2023 - Colorectal Cancer